Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 2 distinct examiners and 2 distinct art units, so the data shows separate examination paths.
ARMSTRONG, SUSANNAH SIPPLE is the busiest examiner, with 1 pending matter. A coordinated technical vocabulary can support both responses, but each action should be developed for its own examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.8% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860369 | INSTANT NANOPARTICLE COMPOSITION AND PREPARATION METHOD THEREFOR | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17760240 | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR TREATING BREAST CANCER | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860369 | INSTANT NANOPARTICLE COMPOSITION AND PREPARATION METHOD THEREFOR | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17760240 | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR TREATING BREAST CANCER | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860369 | INSTANT NANOPARTICLE COMPOSITION AND PREPARATION METHOD THEREFOR | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §102§103§112Other | Non-Final OA | — | Pending | Oct 25, 2024 |
| 17760240 | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR TREATING BREAST CANCER | WHITE, DAWANNA SHAR-DAY | 1627 | §101§102§103§112Other | Non-Final OA | — | Pending | Aug 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Susannah Sipple Armstrong has the most, with 1 of Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.